Insmed (INSM) Stock Analysis – A Brief Overview

By Kim Brooks • Monday, August 26 15:06 • Permanent Link

One of the losers of today's trading session was Insmed. Shares of the Pharmaceutical company plunged -4.7%, and some investors may be wondering if its price of $75.16 would make a good entry point. Here's what you should know if you are considering this investment:

Insmed has moved 264.7% over the last year, and the S&P 500 logged a change of 27.1%
INSM has an average analyst rating of buy and is -15.11% away from its mean target price of $88.53 per share
Its trailing earnings per share (EPS) is $-5.41
Insmed has a trailing 12 month Price to Earnings (P/E) ratio of -13.9 while the S&P 500 average is 28.21
Its forward earnings per share (EPS) is $-4.25 and its forward P/E ratio is -17.7
The company has a Price to Book (P/B) ratio of 322.55 in contrast to the S&P 500's average ratio of 4.71
Insmed is part of the Health Care sector, which has an average P/E ratio of 27.61 and an average P/B of 3.69
The company has a free cash flow of $-306682240, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.